Healthcare, Pharma & Life Sciences

Building the Next Generation of Biologics: How Protein Engineering Platforms Are Catching Up with Complexity

Image
Building the Next Generation of Biologics: How Protein Engineering Platforms Are Catching Up with Complexity

SHERIDAN, WYOMING - December 02, 2025 - As bispecifics, antibody-drug conjugates (ADCs), protein degraders and AI-designed mini-proteins move rapidly into clinical development, discovery teams are confronting a new bottleneck: not target ideas, but the practical engineering and scalable production of molecules that strain conventional biologics workflows.

From monoclonals to a radically more complex biologics toolbox

Monoclonal antibodies still anchor the biologics market, with more than 160 FDA approvals and a dominant share of global drug revenues. But the modality mix is shifting fast. More than 200 ADCs are now in clinical stages, bispecific approvals have climbed to 19 with sales above $12 billion in 2024, and regulators are increasingly supportive of novel protein formats.

AGC Biologics Tackles Speed, Scale and Yield in Next-Generation Microbial Manufacturing

Image
AGC Biologics Tackles Speed, Scale and Yield in Next-Generation Microbial Manufacturing

SHERIDAN, WYOMING - December 02, 2025 - Microbial fermentation is moving back to the center of biologics manufacturing strategy, and contract development and manufacturing organizations (CDMOs) like AGC Biologics are under pressure to turn the platform's greatest strength-speed-into a reproducible, industrial-scale advantage.

Microbial fermentation's resurgence - and its speed problem

Microbial systems have long been valued for fast, efficient production of biologics, and they are now seeing renewed interest for a new generation of therapies. Yet the same speed that makes microbial fermentation attractive also makes it unforgiving. Typical production runs last around 48 hours, leaving very little time to diagnose and correct process deviations once a run is underway.

Six Cell Therapy Holdouts Double Down on CAR T and Autoimmune Plays as Big Pharma Retreats

Image
Six Cell Therapy Holdouts Double Down on CAR T and Autoimmune Plays as Big Pharma Retreats

SHERIDAN, WYOMING - December 02, 2025 - As several large pharmas pull back from cell therapy, a core group of biopharma players is doubling down on CAR T and next-generation approaches, positioning themselves to capture long-term value in oncology and autoimmune disease even as near-term sentiment cools.

Big pharma exits reshape expectations, not potential

Over the past year, the cell therapy field has seen a string of high-profile retreats. Takeda halted new investments in the modality and is offloading its pipeline and platforms after more than eight years of heavy spending. Novo Nordisk followed by terminating all cell therapy work, including a type 1 diabetes program, with nearly 250 roles cut. Belgian biotech Galapagos also shut down its cell therapy business after failing to find a buyer.

HAE Market Pivots to RNA and Gene Therapies as Patient 'Stickiness' Slows Uptake

Image
HAE Market Pivots to RNA and Gene Therapies as Patient ‘Stickiness’ Slows Uptake

SHERIDAN, WYOMING - December 02, 2025 - A wave of first-in-class hereditary angioedema (HAE) therapies is reshaping the U.S. Biotech & Research landscape, but questions remain over how quickly clinicians and patients will adopt these options in an already well-served rare disease market.

New approvals expand hereditary angioedema treatment choices

The HAE pipeline has accelerated dramatically, moving from basic C1 esterase inhibitors to sophisticated RNA-targeting and gene-editing approaches. The disease's life-threatening swelling attacks, including airway involvement, have long justified investment in both acute and prophylactic care, with the first FDA-approved preventive and on-demand therapies arriving in 2008 and 2009.

U.S. Biotech at Risk: How Federal Budget Cuts Undermine Innovation Leadership

Image
U.S. Biotech at Risk: How Federal Budget Cuts Undermine Innovation Leadership

SHERIDAN, WYOMING - December 02, 2025 - As the United States grapples with record-setting government shutdowns and budget fights, the country's biotech and research ecosystem is confronting a deeper structural problem: federal science funding is increasingly unstable, putting early-stage innovation, talent pipelines and long-term competitiveness at risk. For an industry built on long horizons and high-risk discovery, interruptions to programs such as NIH grants and Small Business Innovation Research (SBIR) contracts are more than a temporary setback-they threaten the foundations of America's leadership in biopharma innovation.

Federal science funding as the backbone of U.S. biopharma

Philips debuts cloud-ready web diagnostic viewer to unify imaging access and AI workflows

Image
Philips debuts cloud-ready web diagnostic viewer to unify imaging access and AI workflows

SHERIDAN, WYOMING - November 25, 2025 - Royal Philips has launched Image Management 15, the next generation of its Philips Vue PACS platform, featuring a zero-footprint web diagnostic viewer that brings full radiology workstation capabilities into a standard web browser. Positioned as a cornerstone of Philips' cloud-enabled imaging informatics strategy, the solution is designed to help health systems modernize remote reading, streamline AI integration, and simplify IT across distributed radiology networks.

Anywhere, anytime diagnostic reading via the browser

The new web-based diagnostic viewer is built to address one of radiology's most persistent pain points: lost clinical time due to slow performance and fragmented remote reading setups. Delivering high-performance server-side rendering and workflow automation, it allows radiologists to access advanced clinical tools securely through a browser, without local installation.

Philips and Cortechs.ai deepen AI partnership to scale quantitative neuroimaging in MR

Image
Philips and Cortechs.ai deepen AI partnership to scale quantitative neuroimaging in MR

SHERIDAN, WYOMING - November 25, 2025 - Royal Philips has extended its partnership with quantitative neuroimaging specialist Cortechs.ai to integrate advanced AI-enabled neuroimaging analytics directly into Philips MR systems, giving radiologists faster, more objective and reproducible insights into brain health within their everyday workflows. By combining Philips' next-generation MR technologies with Cortechs.ai's quantitative post-processing software, the collaboration aims to set a new benchmark for precision diagnostics in neurology and strengthen Philips' position in data-driven brain imaging.

Meeting surging demand for brain MR with data-driven insight

Philips' DeviceGuide brings real-time AI navigation into structural heart valve repair

Image
Philips’ DeviceGuide brings real-time AI navigation into structural heart valve repair

SHERIDAN, WYOMING - November 25, 2025 - Royal Philips is introducing DeviceGuide, an AI-powered device tracking solution that brings real-time, 3D navigation support into one of interventional cardiology's most demanding procedures: minimally invasive repair of leaking heart valves. Built on the company's EchoNavigator platform and previewed at London Valves 2025, DeviceGuide is designed to translate complex imaging into intuitive visual guidance, helping structural heart teams perform mitral valve repair with greater clarity, confidence and reproducibility.

AI-guided navigation inside the procedure room

Radiology's Next Chapter: Invisible AI That Quietly Transforms Imaging Workflows

Image
Radiology’s Next Chapter: Invisible AI That Quietly Transforms Imaging Workflows

SHERIDAN, WYOMING - November 25, 2025 - In radiology, the most transformative AI of the coming decade may not be the algorithms that make headlines, but the ones that quietly shave minutes off every case, reduce clicks, and keep worklists flowing smoothly for overburdened imaging teams. That is the vision outlined by Shez Partovi, MD, Chief Innovation Officer and Chief Business Leader Enterprise Informatics at Philips, who argues that the future of AI in radiology is the AI you barely notice - deeply embedded into workflows rather than bolted on as yet another standalone tool.

From "Will it help?" to "How fast can you implement it?"

Philips gains FDA 510(k) clearance for cloud-based Cardiovascular Workspace to accelerate AI in U.S. cardiology

Image
Philips gains FDA 510(k) clearance for cloud-based Cardiovascular Workspace to accelerate AI in U.S. cardiology

SHERIDAN, WYOMING - November 25, 2025 - Philips has received U.S. FDA 510(k) clearance for the latest release of its Cardiovascular Workspace (IntelliSpace Cardiovascular, ISCV), enabling U.S. health systems to deploy the cardiovascular imaging and information management platform as a cloud-hosted, SaaS solution on Philips HealthSuite. The move positions hospitals and cardiology networks to modernize IT, scale integrated diagnostics, and accelerate real-world adoption of AI-enabled cardiovascular workflows.

Cloud-based cardiovascular informatics for U.S. health systems